See more : BASF SE (BAS.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Fortrea Holdings Inc. (FTRE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fortrea Holdings Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Walsin Technology Corporation (2492.TW) Income Statement Analysis – Financial Results
- Yida China Holdings Limited (3639.HK) Income Statement Analysis – Financial Results
- JMS Co.,Ltd. (7702.T) Income Statement Analysis – Financial Results
- Singulus Technologies AG (0RH3.L) Income Statement Analysis – Financial Results
- Ace Edulink Co., Ltd. (6764.TWO) Income Statement Analysis – Financial Results
Fortrea Holdings Inc. (FTRE)
About Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 3.11B | 3.10B | 3.06B | 2.58B |
| Cost of Revenue | 2.69B | 2.47B | 2.45B | 2.09B |
| Gross Profit | 424.00M | 621.70M | 604.40M | 489.10M |
| Gross Profit Ratio | 13.64% | 20.08% | 19.77% | 18.96% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 336.60M | 299.90M | 303.10M | 267.60M |
| Other Expenses | 0.00 | 7.00M | 1.90M | 800.00K |
| Operating Expenses | 457.30M | 396.20M | 469.40M | 386.60M |
| Cost & Expenses | 3.05B | 2.87B | 2.92B | 2.48B |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 69.80M | 132.40M | 200.00K | 0.00 |
| Depreciation & Amortization | 96.40M | 117.60M | 198.80M | 156.40M |
| EBITDA | 166.90M | 354.60M | 335.20M | -175.80M |
| EBITDA Ratio | 5.37% | 10.62% | 9.87% | 25.46% |
| Operating Income | 63.10M | 185.20M | 114.30M | -314.20M |
| Operating Income Ratio | 2.03% | 5.98% | 3.74% | -12.18% |
| Total Other Income/Expenses | -62.00M | 1.10M | 22.10M | -434.70M |
| Income Before Tax | 1.10M | 58.90M | 136.40M | -332.20M |
| Income Before Tax Ratio | 0.04% | 1.90% | 4.46% | -12.87% |
| Income Tax Expense | 4.50M | 500.00K | 38.40M | 27.00M |
| Net Income | -3.40M | 58.40M | 98.00M | -359.20M |
| Net Income Ratio | -0.11% | 1.89% | 3.21% | -13.92% |
| EPS | -0.04 | 0.66 | 1.11 | -4.06 |
| EPS Diluted | -0.04 | 0.64 | 1.11 | -4.06 |
| Weighted Avg Shares Out | 88.80M | 88.40M | 88.40M | 88.40M |
| Weighted Avg Shares Out (Dil) | 88.80M | 91.10M | 88.40M | 88.40M |
Fortrea Holdings Inc. (FTRE) Reports Q2 Loss, Lags Revenue Estimates
Fortrea Reports Second Quarter 2024 Results
Earnings Preview: Fortrea Holdings Inc. (FTRE) Q2 Earnings Expected to Decline
Fortrea Announces Date for Second Quarter 2024 Financial Results and Conference Call
Fortrea Appoints Robert Parks as Chief Accounting Officer
Fortrea Launches AI Innovation Studio to Galvanize Technology and Human Solutions to Improve Clinical Trial Delivery
Fortrea to Participate in Virtual Fireside Chat with Evercore ISI
Fortrea Completes Divestiture of Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners
Fortrea to Present at the Jefferies Global Healthcare Conference
Fortrea Introduces Comprehensive Solution to Improve Diversity and Inclusion in Clinical Research
Source: https://incomestatements.info
Category: Stock Reports